Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

N/ACompletedNCT00481962

Wyeth is now a wholly owned subsidiary of Pfizer180 enrolled

Overview

The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Peritonitis

Interventions

TygacilDRUG

Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of secondary peritonitis * Treatment in an ICU * Patient age \>18 years

Locations (1)

Unnamed facility

Multiple Cities, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.